- Home
- LPCN vs NRXS Comparison
LPCN vs NRXS Comparison
Compare LPCN & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- NRXS
- Stock Information
- Founded
- LPCN 1997
- NRXS 2011
- Country
- LPCN United States
- NRXS United States
- Employees
- LPCN N/A
- NRXS N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- LPCN Health Care
- NRXS
- Exchange
- LPCN Nasdaq
- NRXS Nasdaq
- Market Cap
- LPCN 16.1M
- NRXS 13.0M
- IPO Year
- LPCN N/A
- NRXS 2023
- Fundamental
- Price
- LPCN $3.17
- NRXS $2.61
- Analyst Decision
- LPCN Strong Buy
- NRXS
- Analyst Count
- LPCN 2
- NRXS 0
- Target Price
- LPCN $9.00
- NRXS N/A
- AVG Volume (30 Days)
- LPCN 71.7K
- NRXS 4.9M
- Earning Date
- LPCN 05-08-2025
- NRXS 05-12-2025
- Dividend Yield
- LPCN N/A
- NRXS N/A
- EPS Growth
- LPCN N/A
- NRXS N/A
- EPS
- LPCN N/A
- NRXS N/A
- Revenue
- LPCN $3,674,834.00
- NRXS $2,934,945.00
- Revenue This Year
- LPCN N/A
- NRXS $138,883.78
- Revenue Next Year
- LPCN N/A
- NRXS $118.59
- P/E Ratio
- LPCN N/A
- NRXS N/A
- Revenue Growth
- LPCN N/A
- NRXS 27.52
- 52 Week Low
- LPCN $2.68
- NRXS $1.33
- 52 Week High
- LPCN $11.79
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- LPCN 43.78
- NRXS 50.48
- Support Level
- LPCN $3.00
- NRXS $2.57
- Resistance Level
- LPCN $3.49
- NRXS $2.82
- Average True Range (ATR)
- LPCN 0.34
- NRXS 0.44
- MACD
- LPCN -0.05
- NRXS -0.05
- Stochastic Oscillator
- LPCN 16.50
- NRXS 10.25
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).